SynthesisBMC infectious diseases2025
Spatio-temporal trends of artemisinin-based combination therapy efficacy from 2010 to 2024 in sub-Saharan Africa: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Spatio-temporal trends of the prevalence of Plasmodium falciparum antimalarial drug resistance markers across sub-Saharan Africa from 2010 to 2024: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Population pharmacokinetics of lumefantrine in pregnant and non-pregnant Nigerian women receiving efavirenz-based antiretroviral therapy.European journal of clinical pharmacology · 2026Article
- Artificial intelligence for precision malaria control: transforming surveillance, prediction, and intervention strategies.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArtemisinin-based Combination Therapy (ACT) has contributed to the reduction of malaria burden in sub-Saharan Africa. However, the number of global cases has risen since 2015. Resistances to artemisinin reported from Southeast Asia and recently emerged in sub-Saharan Africa might threaten ACT efficacy. We conducted a systematic review and meta-analysis on ACT efficacy trends in sub-Saharan Africa from January 2010 to December 2024.
methodsWe systematically searched PubMed/Medline and Scopus for studies published between 2010 and 2024 that met the World Health Organisation (WHO) criteria for therapeutic efficacy studies. Two reviewers have independently assessed the eligibility criteria and extracted data. ACT efficacy was measured using the PCR-corrected Adequate Clinical and Parasitological Response (ACPR) at day 28 or 42. Meta-analysis was conducted using R.
resultsThe meta-analysis included 116 studies with a total of 17,341 participants for artemether-lumefantrine (AL), 8,855 for artesunate-amodiaquine (AS-AQ), 5,544 for dihydroartemisinin-piperaquine (DHA-PPQ), and 346 for artesunate-pyronaridine (AS-PY). Over the period under review, from 2010 to 2024, the PCR-corrected ACPR for AS-AQ, DHA-PPQ, and AS-PY remained above 90% across sub-Saharan Africa. For AL, the PCR-corrected ACPR remained high between 2010 and 2014, consistently exceeding 90% (range: 91-100%). However, from 2015 to 2024, the efficacy showed greater variability, with PCR-corrected ACPR values ranging from 74% to 100%. Notably, this efficacy dropped below the 90% threshold in several countries, including Kenya (2017), Burkina Faso (2018), Uganda (2019), and Nigeria (2020).
conclusionsWhile AS-AQ, DHA-PPQ, and AS-PY have maintained high efficacy over time in sub-Saharan Africa, there is a concern about the declining efficacy of AL in some West and East African countries. Our findings suggest that AS-PY could be a promising candidate for inclusion in first-line malaria treatments to address the declining efficacy of AL. Continuous monitoring of ACT efficacy, innovative and efficient control strategies are crucial to prevent the spread of antimalarial drug resistance. REGISTRATION: PROSPERO number CRD42023432718.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.